Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 968

1.

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R.

J Neurol Neurosurg Psychiatry. 2016 Apr 25. pii: jnnp-2015-312601. doi: 10.1136/jnnp-2015-312601. [Epub ahead of print]

PMID:
27113605
2.

Red blood cell alloimmunization in transfused patients with bone marrow failure syndromes.

Cohen D, Hartung H, Evans P, Friedman DF, Chou ST.

Transfusion. 2016 Apr 15. doi: 10.1111/trf.13608. [Epub ahead of print]

PMID:
27080340
3.

Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of 'Chinese restaurant syndrome'.

Leussink VI, Hartung HP, Stüve O, Kieseier BC.

J Neurol. 2016 Apr 8. [Epub ahead of print] No abstract available.

PMID:
27060083
4.

Steering through complexity: management approaches in multiple sclerosis.

Cree BA, Hartung HP.

Curr Opin Neurol. 2016 Jun;29(3):263-71. doi: 10.1097/WCO.0000000000000332.

PMID:
27058222
5.

Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives.

Aktas O, Albrecht P, Hartung HP.

Curr Opin Neurol. 2016 Jun;29(3):199-204. doi: 10.1097/WCO.0000000000000327.

PMID:
27035900
6.

Recent achievements in stem cell-mediated myelin repair.

Jadasz JJ, Lubetzki C, Zalc B, Stankoff B, Hartung HP, Küry P.

Curr Opin Neurol. 2016 Jun;29(3):205-12. doi: 10.1097/WCO.0000000000000323.

PMID:
27035898
7.

Repair strategies for multiple sclerosis: challenges, achievements and perspectives.

Stankoff B, Jadasz JJ, Hartung HP, Küry P, Zalc B, Lubetzki C.

Curr Opin Neurol. 2016 Jun;29(3):286-92. doi: 10.1097/WCO.0000000000000325.

PMID:
27035897
8.

Thalamic and Entorhinal Network Activity Differently Modulates the Functional Development of Prefrontal-Hippocampal Interactions.

Hartung H, Brockmann MD, Pöschel B, De Feo V, Hanganu-Opatz IL.

J Neurosci. 2016 Mar 30;36(13):3676-90. doi: 10.1523/JNEUROSCI.3232-15.2016.

PMID:
27030754
9.

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D.

Mult Scler. 2016 Mar 22. pii: 1352458516638941. [Epub ahead of print]

PMID:
27003945
10.

Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.

Leussink VI, Stettner M, Warnke C, Hartung HP.

J Peripher Nerv Syst. 2016 Mar 10. doi: 10.1111/jns.12169. [Epub ahead of print]

PMID:
26968589
11.

Pushing Forward: Remyelination as the New Frontier in CNS Diseases.

Kremer D, Göttle P, Hartung HP, Küry P.

Trends Neurosci. 2016 Apr;39(4):246-63. doi: 10.1016/j.tins.2016.02.004. Epub 2016 Mar 7. Review.

PMID:
26964504
12.

Disease-modifying therapies and infectious risks in multiple sclerosis.

Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK.

Nat Rev Neurol. 2016 Apr;12(4):217-33. doi: 10.1038/nrneurol.2016.21. Epub 2016 Mar 4. Review.

PMID:
26943779
13.

Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.

Ingwersen J, Wingerath B, Graf J, Lepka K, Hofrichter M, Schröter F, Wedekind F, Bauer A, Schrader J, Hartung HP, Prozorovski T, Aktas O.

J Neuroinflammation. 2016 Feb 26;13:48. doi: 10.1186/s12974-016-0512-z.

14.

Pseudomonas aeruginosa and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes.

Weber A, Zimmermann C, Mausberg AK, Dehmel T, Kieseier BC, Hartung HP, Hofstetter HH.

Infect Immun. 2016 Apr 22;84(5):1413-23. doi: 10.1128/IAI.00905-15. Print 2016 May.

PMID:
26902726
15.

Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy.

Stettner M, Hinrichs L, Guthoff R, Bairov S, Petropoulos IN, Warnke C, Hartung HP, Malik RA, Kieseier BC.

Ann Clin Transl Neurol. 2015 Dec 28;3(2):88-100. doi: 10.1002/acn3.275. eCollection 2016 Feb.

16.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators.

Lancet. 2016 Mar 12;387(10023):1075-84. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28.

PMID:
26827074
17.

More on PML in Patients Treated with Dimethyl Fumarate.

Reich K, Hartung HP, Lebwohl M.

N Engl J Med. 2016 Jan 21;374(3):294-5. doi: 10.1056/NEJMc1512228#SA1. No abstract available.

PMID:
26789900
18.

CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.

Kremer D, Cui QL, Göttle P, Kuhlmann T, Hartung HP, Antel J, Küry P.

PLoS One. 2016 Jan 7;11(1):e0146503. doi: 10.1371/journal.pone.0146503. eCollection 2016.

19.

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Ingwersen J, Aktas O, Hartung HP.

Neurotherapeutics. 2016 Jan;13(1):47-57. doi: 10.1007/s13311-015-0412-4.

PMID:
26701666
20.

Fabrication of free-standing lithium niobate nanowaveguides down to 50 nm in width.

Geiss R, Sergeyev A, Hartung H, Solntsev AS, Sukhorukov AA, Grange R, Schrempel F, Kley EB, Tünnermann A, Pertsch T.

Nanotechnology. 2016 Feb 12;27(6):065301. doi: 10.1088/0957-4484/27/6/065301. Epub 2015 Dec 18.

PMID:
26684215
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk